NASDAQ OMX

Informa's Annual Clinical and Research Excellence Awards Return for Third Year

26.6.2017 16:48 | NASDAQ OMX

Dela

BOSTON, June 26, 2017 (GLOBE NEWSWIRE) -- Informa's Pharma Intelligence has today announced that the third annual Clinical and Research Excellence (CARE) Awards are now open for nominations.

Pharma Intelligence - the world's leading provider of clinical and research intelligence and analysis, and home of leading brands such as Scrip, Pink Sheet and Biomedtracker - will host the awards which recognize and celebrate outstanding achievements and stand-out performers in the global R&D space.

Nominations for the CARE Awards are free and all submissions should be made via the online entry form available at www.clinicalresearchexcellence.com by December 23. All entries will be assessed by a panel of distinguished industry experts and the winners will be announced at the CARE Awards ceremony on April 25, 2018 at the Boston Harbor Hotel.

"The success of last year's CARE Awards was testament to the original mission of the CARE Awards: to recognize the extraordinary achievements of the dedicated professionals working in biopharmaceutical clinical research. The event really brings the industry together to celebrate the individuals and companies that continuously strive for excellence in everything they do and are making a real difference to lives across the world," says Doro Shin, Pharma Intelligence's Thought Leadership Manager.

"Last year's admirable winners included Kite Pharma for its groundbreaking CAR-T therapy, and IBM Watson Health, Novartis & Highlands Oncology for their collaborative, and transformative, technological development. The event was a huge success and we're looking forward to replicating this in April," states Karen Currie, Executive Director of Trialtrove, Sitetrove, and Pharmaprojects.

The third annual CARE Awards will once again honor the achievements of the dedicated individuals, teams and organizations committed to advancing human health through clinical research, despite the day-to-day challenges. The eleven categories for the awards have been designed to showcase key accomplishments, including excellence in rare disease drug development, clinical trials conduct and design, technological advancements, and collaborative efforts between teams.

This year's categories are as follows:

  • Most Successful Early Phase Research (Preclinical & Phase I)
  • Excellence in Rare Disease Drug Development
  • Best Patient Centric Clinical Trial
  • Clinical Research Team of the Year
  • Most Innovative Clinical Trial Design
  • Clinical Trial Result of the Year
  • Best Patient-Focused Technological Development
  • Best Sponsor-Focused Technological Development
  • Clinical Partnership of the Year
  • Best in Health Economics & Outcomes Research
  • Lifetime Achievement

"The pharmaceutical industry is driven by an ambition to change the healthcare landscape across the world and improve quality of life. A lot of effort goes into every aspect of the R&D pipeline and the CARE Awards specifically highlight and applaud the commitment and dedication of those individuals, teams and organizations involved," adds Linda Blackerby, President of Pharma Intelligence. "We encourage nominations from across the globe, and look forward to celebrating the achievements of the winners and commending all nominees for their work."

Contact
Karen Currie
Executive Director, Editorial
Contact:  617-639-5594 
Email: Karen.currie@informa.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Informa Business Intelligence via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.

Senaste pressmeddelandena från NASDAQ OMX

ATTO ThunderLink® enables VMware® ESXi(TM) for Mac Pro®24.8.2017 10:00Pressmeddelande

AMHERST, N.Y., Aug.  24, 2017  (GLOBE NEWSWIRE) -- ATTO Technology, Inc., a global leader of storage, network connectivity and infrastructure solutions for data-intensive computing environments for nearly 30 years, today is proud to announce their 16Gb and 8Gb Fibre Channel ThunderLink® Thunderbolt(TM) devices have achieved VMware Ready(TM) status for ESXi(TM). ATTO ThunderLink devices are the only purpose built Thunderbolt product designed to connect virtualized Mac hardware to 16Gb and 8Gb Fibre Channel storage solutions within VMware® VSphere environments. This provides a new and efficient solution for Apple technologies application development and testing environments, virtual desktop infrastructure and cloud hosting or shared private cloud. "By utilizing an ATTO ThunderLink in a VMware environment users can now take advantage of a one of a kind solution to bring virtualized Macs into test and development environments," said Tom Kolniak, Senior Director of

Karolinska Development - Delårsrapport för januari - juni 2017, inbjudan till telefonkonferens och webbpresentation24.8.2017 08:00Pressmeddelande

STOCKHOLM den 24 augusti 2017. Karolinska Development AB (Nasdaq Stockholm: KDEV) kommer att offentliggöra delårsrapporten för januari - juni 2017 efter att marknaden har stängt den 29 augusti 2017. Bolaget kommer även att hålla en telefonkonferens och webbpresentation den 30 augusti klockan 14.00 CEST. Vänligen ring in på något av följande telefonnummer några minuter före telefonkonferensens start: Från Sverige: +46 (0) 8 505 564 74 Från USA: +1 855 753 22 30 Från Storbritannien: +44 (0) 20 336 453 74 Webbpresentationen kan samtidigt nås från: https://edge.media-server.com/m6/p/7zkrjqvs Presentatör: Viktor Drvota, VD. För ytterligare information, vänligen kontakta : Viktor Drvota, VD, Karolinska Development AB Tel: +46 73 982 52 02, e-mail: viktor.drvota@karoli

Karolinska Development - Interim Report (January-June 2017) - Invitation to conference call and webcast24.8.2017 08:00Pressmeddelande

STOCKHOLM - August 24, 2017. Karolinska Development AB (Nasdaq Stockholm: KDEV) will publish its Interim Report - January-June 2017 on August 29, 2017 after market closure. The company will also host a conference call and an online presentation on August 30, at 2 pm CEST. Please dial in at one of the following numbers a few minutes before the start of the conference call: The Company will host a conference call on August 30, 2017 at 2 pm CEST. Please dial in at one of the following numbers a few minutes before the start of the conference call: From Sweden: +46 (0) 8 505 564 74 From the US: +1 855 753 22 30 From the UK: +44 (0) 20 336 453 74 The presentation will also be webcast and can be accessed from the following web address: https://edge.media-server.com/m6/p/7zkrjqvs Host: Viktor Drvota, CEO. For further information, please contact: Viktor Drvota, CEO, Karolinska Dev

PayByPhone Appoints Francis Dupuis as new CEO24.8.2017 01:14Pressmeddelande

VANCOUVER, British Columbia, Aug. 23, 2017 (GLOBE NEWSWIRE) -- PayByPhone, the global leader in mobile parking payments, today announced that it has appointed Francis Dupuis as President and Chief Executive Officer effective August 23rd, 2017. Kush Parikh, former President and CEO, has stepped down from the role after his successful 3.5-year term with the business. During his time at PayByPhone, Kush led the business to profitability, established a strong focus on end customers and was pivotal in its ground-breaking sale to Volkswagen Financial Services.  "With more than 20 years of experience in the software industry and a deep product background, Francis is exactly the kind of leader we need to further grow and innovate in the parking market on an international scale," said Stefan Imme, Head of M&A and Investment Management at Volkswagen Financial Services AG. Francis, a long-standing member of the executive team at PayByPhone, takes the reins at a

Kommuniké från extra bolagsstämma i LeoVegas, 23 augusti 201723.8.2017 16:34Pressmeddelande

Extra bolagsstämma i LeoVegas AB (publ) ("LeoVegas" eller "Bolaget") hölls idag den 23 augusti 2017 varvid aktieägarna fattade följande beslut. Beslut om incitamentsprogram till anställda Stämman beslutade enhälligt, i enlighet med styrelsens förslag, att emittera högst 1 000 000 teckningsoptioner med avvikelse från aktieägarnas företrädesrätt till följd varav Bolagets aktiekapital kan komma att öka med högst 12 000,000022 euro. Teckningsoptionerna medför rätt till nyteckning av aktier i Bolaget. Incitamentsprogrammet ersätter det från årsstämman den 17 maj 2017 beslutade programmet i vilket samtliga teckningsoptioner makulerats efter beslut av styrelsen den 23 juli 2017 som registrerades hos Bolagsverket den 26 juli 2017. Rätt att teckna teckningsoptionerna ska tillkomma Gears of Leo AB ("Dotterbolaget") med rätt och skyldighet att, vid ett eller flera tillfäl

Announcement from LeoVegas's extra general meeting, 23 August 201723.8.2017 16:34Pressmeddelande

The extra general meeting ("EGM") of LeoVegas AB (publ) ("LeoVegas" or the "Company") was held today on 23 August 2017 and the following resolutions were passed. Resolution regarding incentive program for employees The EGM resolved unanimously, in accordance with the board of directors' proposal to issue a maximum of 1,000,000 warrants, with deviation from the shareholders preferential rights, which may result in a maximum increase in the Company's share capital of EUR 12,000.000022. The warrants shall entitle to subscription of new shares in the Company. The incentive program replaces the program resolved on by the annual general meeting held on 17 May 2017 in which all issued warrants have been cancelled in accordance with the board of directors resolution on 23 July 2017 which was registered with the Swedish Companies registration Office on 26 July 2017. The

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum